A decision support system for the treatment of esophageal cancer
Mistry H. et al, (2018), CANCER RESEARCH, 78
INCIDENCE AND MANAGEMENT OF IMMUNOTHERAPY-INDUCED COLITIS IN A TERTIARY IBD CENTRE - CLINICAL PRACTICE DATA
Gupta T. et al, (2018), GUT, 67, A186 - A187
Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals.
Morrell L. et al, (2018), BMC Health Serv Res, 18
Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin lymphoma (HL): Impact of cycle 2 PET result on modified progression-free survival (mPFS).
Chen RW. et al, (2018), JOURNAL OF CLINICAL ONCOLOGY, 36
First-in-class phase I study evaluating MP0250, a VEGF and HGF neutralizing DARPIN molecule, in patients with advanced solid tumors.
Azaro A. et al, (2018), JOURNAL OF CLINICAL ONCOLOGY, 36
Improving outcomes with brentuximab vedotin (BV) plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma.
Straus DJ. et al, (2018), JOURNAL OF CLINICAL ONCOLOGY, 36
Indirect treatment comparison of nivolumab versus placebo as an adjuvant therapy for resected melanoma.
Shoushtari AN. et al, (2018), Journal of Clinical Oncology, 36, 9593 - 9593
Cell-extrinsic hematopoietic impact of Ezh2 inactivation in fetal liver endothelial cells.
Neo WH. et al, (2018), Blood, 131, 2223 - 2234
Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.
Armand P. et al, (2018), J Clin Oncol, 36, 1428 - 1439
Translational study identifies XPF and MUS81 as predictive biomarkers for oxaliplatin-based peri-operative chemotherapy in patients with esophageal adenocarcinoma.
MacGregor TP. et al, (2018), Scientific reports, 8, 7265 - 7265
CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial.
Gleeson M. et al, (2018), Lancet Haematol, 5, e190 - e200
Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.
Juric D. et al, (2018), J Clin Oncol, 36, 1291 - 1299
BCR-ABL1 kinase domain mutation screening using next generation sequencing in CML and Ph plus ALL patients
Kizilors A. et al, (2018), BRITISH JOURNAL OF HAEMATOLOGY, 181, 45 - 45
Feasibility of recruitment of patients with Myeloproliferative Neoplasms into the TAP funded TAMARIN study
Harrison C. et al, (2018), BRITISH JOURNAL OF HAEMATOLOGY, 181, 187 - 187
Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.
Roemer MGM. et al, (2018), J Clin Oncol, 36, 942 - 950
Nivolumab Treatment Beyond Investigator-Assessed Progression: Outcomes in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma From the Phase 2 CheckMate 205 Study
Cohen JB. et al, (2018), BRITISH JOURNAL OF HAEMATOLOGY, 181, 87 - 88
Pharmacodynamic and Pharmacokinetic Markers For Anti-angiogenic Cancer Therapy: Implications for Dosing and Selection of Patients.
Morotti M. et al, (2018), Eur J Drug Metab Pharmacokinet, 43, 137 - 153
Ruxolitinib induces changes in histone modification status in patients entered into the MAJIC clinical trial
McPherson S. et al, (2018), BRITISH JOURNAL OF HAEMATOLOGY, 181, 47 - 48